

Immunicum and DCprime combining forces

to establish leadership in cell-based
immunotherapies to fight cancer




Sven Rohmann
CEO Immunicum



Erik Manting
CEO DCprime

November 19th, 2020
Financial Hearings



Disclaimer


This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding Immunicum's view on strategy, future operations, future clinical development plans and objectives, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate", "believe", "estimate", "expect", "intend", "may", "plan", "predict", "project", "target", "potential", "will", "would", "can", "could", "shall", "should", "continue" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements contained in this presentation reflect Immunicum's current views with respect to future events, and Immunicum assumes no obligation to update any forward-looking statements except as required by applicable law. Our actual results and/or actual events could differ materially from those anticipated in forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, chemistry, manufacturing and controls, regulatory oversight, product commercialization, upholding of intellectual property rights or intellectual property claims, general market developments and other risks, uncertainties and factors within and outside of our control. Given these risks, uncertainties and other factors, you should not place undue reliance on forward-looking statements, and we assume no obligation to update forward-looking statements, even if new information becomes available in the future, or to provide information regarding the reasons why actual outcome, events or results could differ materially from those anticipated in the forward-looking statements, except as required by law. You should instead make or, if you are not qualified to do so, seek the assistance of qualified and professional counsel in making, an independent and adequately substantiated assessment of us, our operations, current and future activities and commercial potential based on all available information about us, as presented in financial reports, press releases and in other contexts, and about the business fields and markets in which we are active, as presented in, inter alia, scientific and other publications (although we do not assume any responsibility for information about us obtained from third parties).

Building Leadership in Allogeneic Dendritic Cell Biology

- 1 • Establish global leader in immunotherapy based on allogeneic dendritic cell biology**
 - Built on decades of combined immuno-oncology and cell therapy expertise
- 2 • Rich combined pipeline in both solid and blood-borne tumors**
 - Two Phase II programs supporting multiple near-term data read-outs
 - Programs benefiting from RMAT and Orphan Drug Designation
 - Synergistic cell-based approaches based on intratumoral immune priming and relapse vaccination
 - Multiple preclinical programs to fuel future pipeline expansion with next-generation cell therapies
- 3 • Building a fully-integrated company with specialized in-house R&D facilities**
 - Two lean and complementary organizations
 - R&D, process development and manufacturing, late-stage development and commercial expertise under one roof
- 4 • Obtaining a new anchor investor through Van Herk Investments**
 - A leading European investor in life science with several large shareholdings including Zealand Pharma, BioInvent, Galapagos and successful trade sale exits in Ablynx (Sanofi), Crucell (J&J)



Complementary Approaches to Expand Therapeutic Reach and Market Potential



Leading expertise in allogeneic DC biology

Immunicum Company Overview



- Leader in allogeneic cell therapies for solid tumors
- Founded in 2002, spin-off of Sahlgrenska University, Gothenburg, Sweden
- Listed at Nasdaq First North in 2013, uplisted to Nasdaq Stockholm main market in 2018
- Lead product ilixadencel in Phase II, and more than 100 patients treated in several studies to date



Indication	Preclinical	Phase I	Phase II
Kidney cancer	MERECA study		
Liver cancer			
GIST			
HNSCC	ILIAD study		
NSCLC	ILIAD study		
Gastric cancer	ILIAD study		





Experienced and Complementary Management Team



Sven Rohmann
CEO
MD, PhD, EMBA



Peter Suenart
CMO
MD, PhD



Alex Karlsson-Parra
CSO & Founder
MD, PhD, Adj. Prof.



Sharon Longhurst
Head of CMC
PhD



Sijme Zeilemaker
COO
MSc



Margareth Jorvid
Head of Regulatory Affairs & QA
MSc, MBA




Peter Hein
Interim CFO
MSc

DCprime Company Overview



- Leader in cancer relapse vaccines
- Founded in 2005, spin-off of Amsterdam UMC
- ~20 employees with majority in research and process development
- Labs and offices at the Leiden Bio Science Park, a leading life sciences hub in the Netherlands
- Supported by Van Herk, one of the largest European investors in biotechnology



Experienced Management and Supervisory Board (SB)



Erik Manting, PhD - CEO

- PhD in Molecular Microbiology
- Several years of research experience in immunology
- 15 years in commercial and management roles in banking, latest at Kempen & Co Life Sciences



Jeroen Rovers, MD, PhD - CMO

- MD, PhD in Medicine
- 15 years of industry experience in a variety of medical roles, including CMO at Kiadis Pharma (KDS:NA)
- Diploma in Pharmaceutical Medicine from Basel University



Dharminder Chahal – Chairman of the SB

- Van Herk Investments, CEO SkylineDx, SB member BioInvent and VitalneXt, AB member several venture capital firms



Andrea van Elsas, PhD – SB member


- Venture Partner Third Rock Ventures, former CSO Aduro Biotech, VP Research AM Pharma
- Lead anti-PD1 program at Organon that originated Keytruda



Hans Preusting, PhD, MBA – SB member


- CEO Synerkine Pharma, former CBO uniQure and Director Process Development and Manufacturing AMT

DCprime's Relapse Vaccination Approach Represents a New Therapeutic Paradigm



- Tumor recurrence has become the largest medical challenge in cancer treatment
- Relapse vaccination boosts the immune system to control residual disease following initial treatment and to prevent or delay tumor recurrence
- Applicable to both blood-borne and solid tumors

DCprime's Lead Asset DCP-001 is a Promising, Innovative, Cell-based Relapse Vaccine



- Proprietary cell line and manufacturing process
- Combination platform for CAR-T and other immunotherapies

Off-the-shelf

Derived from proprietary DCOne® cells, frozen product

Simple administration

Bedside thawing, intradermal injection

Benign safety profile

Evaluated as safe, feasible and well-tolerated in Phase I clinical trial

High unmet medical need

Addresses a high medical need in relapse vaccination

Polyvalent


Multiple endogenous tumor-associated antigens

Immunogenic

Efficiently processed, triggers multifunctional immune responses

DCprime's Lead Asset DCP-001 Showed Promising Overall Survival in Phase I/II

Overall survival Ph I/II trial¹



Longest survivor: 71 months (median 36 months)

Promising first signs of efficacy in this challenging population of AML patients

Patient population


- Acute myeloid leukemia (AML) is an aggressive type of blood cancer, frequently leading to relapse and death
- Patients treated had a very high risk for relapse and disease progression, with no bone marrow transplant option available
- Median relapse-free survival: 14 months
- Median overall survival: 36 months

Phase II ongoing

- ADVANCE II trial selects 20 AML patients based on CR status and with minimal residual disease
- Interim data to be presented at ASH 2020

¹ Based on study data published in Van de Loosdrecht et al. (2018) *Cancer Immunology, Immunotherapy*; 67:1505–1518 and presented at ASH 2019 (L. Janssen et al. (2019) *Blood*, 134 (Supplement_1): 1381)


Ongoing Clinical Studies of Immunicum & DCprime: Planned Milestones



ASH: American Society of Hematology
Annual Meeting, December 5-8, 2020

Highly Complementary Organization

- Lean and highly complementary organizations
 - **Leadership:** International leadership team
 - **Board Level:** Profound industry, financial and scientific expertise
 - **R&D and Ops:** Pioneers in allogeneic dendritic cell biology, strong expertise in process development and manufacturing, in-house R&D facilities
- Located in two leading European biotech hubs, Stockholm and Leiden
 - Ability to tap into two deep talent pools, attract international talent and investors
- Listed on Nasdaq Stockholm
 - Established as listed company and financial runway into beginning of 2022
 - Strong new anchor investor, Van Herk, one of the most successful investors in EU biopharma
- Joint ambition to build a leading, global biopharmaceutical company



Key Terms, Conditions and Timelines of the Transaction

Merger

- Immunicum to acquire all outstanding shares of DCprime
- Merger to Establish Leader in Cell-Based Cancer Immunotherapies

Financials

- The combination will take place through an issue in kind of approx. 73.9m new Immunicum shares
- The combined entity will have a cash runway until beginning of 2022, benefitting from immediate synergies
- The largest shareholders in the combined entity will be Van Herk Investments and AP4

Management

- Erik Manting, PhD, will join the Immunicum management team as the new CBO and deputy CEO
- Jeroen Rovers, MD, PhD, will ascertain the role of Managing Director of DCprime in the combined entity
- Andrea van Elsas, PhD, and Dharminder Chahal will join the Board of Directors of Immunicum¹


Timelines

- December 18th, 2020 - Extraordinary General Meeting of Immunicum
- End of December 2020 - Closing of the Transaction

1. Subject to EGM approval

Complementary Approaches to Build Leadership in Allogeneic Dendritic Cell Biology

 IMMUNICUM



Complementary therapeutic approaches of intratumoral priming and cancer relapse vaccination



Strong pipeline in solid tumors, instant expansion into blood-borne tumors



Expanding near-term clinical development progress and long-term value creation



Rich and deep research pipeline as basis for immuno-oncology leader




International corporate profile supported by renowned institutional investors



Synergistic organization with strong in-house research and process development

DC PRIME



Immunicum and DCprime combining forces

to establish leadership in cell-based
immunotherapies to fight cancer



Sven Rohmann
CEO Immunicum



Erik Manting
CEO DCprime

November 19th, 2020
Financial Hearings

